NRx Pharmaceuticals (NRXP) investor relations material

Executive summary

• Achieved key milestones: $20M+ public offering, FDA ANDA review cycle for preservative-free ketamine with no major drug deficiencies and only a vial attestation pending, selection as Prime Contractor for SPARC-TMS trial with $11.5M+ non-dilutive funding potential, and acquisition of GeNeuro assets expanding the pipeline into neuroimmune disorders with strong NIH and governmental partnerships.

• Expanded clinical footprint with HOPE clinics, new sites in Florida, and two subsidiaries focused on military/first responder and neuroimmune therapeutics; became first US commercial site to use Zeta Surgical's FDA-cleared TMS navigation system.

• Advanced NRX-100 NDA using Real World Evidence from over 65,000 patients, leveraging recent federal support for such data in depression treatment approvals.

• Initiated commercial-scale manufacturing for launch stock of 5 million ketamine doses, with post-launch capacity of 1 million units/month.

• Appointed first Chief Commercial Officer and retained a commercial launch team for ketamine.

Financial highlights

• Net loss of $17.9M for H1 2026, improved from $23.1M in H1 2025; net loss of $16.5M for Q2 2026, improved from $17.6M in Q2 2025.

• Revenue of $2.2M for H1 2026, all from Dura clinical services post-acquisition.

• Cash and cash equivalents of $26.7M as of June 30, 2026, up from $7.8M at year-end 2025, primarily due to public offerings.

• Operating cash outflow of $13.2M for H1 2026; financing activities provided $33M, mainly from equity offerings.

• Net operating loss was $11.3M versus $7.6M year-over-year, driven by R&D and SG&A for commercial launch preparation.

Outlook and guidance

• Management expects continued operating losses through 2026 as integration and expansion of clinical operations continue.

• Sufficient capital to fund drug development through Q1 2027; additional financing may be pursued for ongoing operations.

• Targeting FDA approval and commercial launch of preservative-free ketamine in 2026 and aiming to finalize NRX-100 NDA for depression in 2027, leveraging new federal guidance on Real World Evidence.

• Revenue expected to increase as Dura is fully integrated and clinical capacity expands.

• GeNeuro's GNK-301 first-in-human trial planned for July 2027, with potential for substantial future federal funding.